Preventing Paclitaxel-Induced Peripheral Neuropathy: A Phase II Trial of Vitamin E Supplementation

Journal of Pain and Symptom Management

Volumn 32, Issue 3, 2006, Pages 237-244

  Argyriou, Andreas A ^a   Chroni, Elisabeth ^a   Koutras, Angelos ^a   Iconomou, Gregoris ^a   Papapetropoulos, Spiridon ^a   Polychronopoulos, Panagiotis ^a   Kalofonos, Haralabos P ^a  

^a EMG Laboratory   (Greece)

Author keywords

chemotherapy; neuroprotection; Paclitaxel; peripheral neuropathy; vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; PACLITAXEL; PLACEBO;

ADULT; ALOPECIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FEVER; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPHYSIOLOGY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; INCIDENCE; LUNG CANCER; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROLOGIC EXAMINATION; NEUROTOXICITY; OVARY CANCER; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREVENTIVE MEDICINE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; DIETARY SUPPLEMENTS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME; VITAMIN E;

EID: 33748206400     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2006.03.013     Document Type: Article

References (29)

1. Rowinsky E.K., Cazenave L.A., and Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82 (1990) 1247-1259
2. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., et al. Clinical toxicities encountered by paclitaxel (Taxol). Semin Oncol 20 (1993) 1-15
3. Halliwell B., and Gutteridge J.M.C. Free radicals in biology and medicine (1993), Oxford University Press, Oxford 188-276
4. Leonetti C., Biroccio A., Gabellini C., et al. Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int J Cancer 104 2 (2003) 243-250
5. Weijl N.I., Hopman G.D., Wipkink-Bakker A., et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol 9 12 (1998) 1331-1337
6. Argyriou A.A., Chroni E., Koutras A., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64 1 (2005) 26-31
7. In: Dyck P.J., and Thomas P.K. (Eds). Peripheral neuropathy. 3rd ed. (1993), WB Saunders, Philadelphia, PA 1310-1317
8. Kleyweg R.P., Van der Meché F.G.A., and Schmitz P.I.M. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 14 (1991) 1103-1109
9. Kimura J. Electrodiagnosis in diseases of nerve and muscle, principles and practice. 3rd ed. (2001), Oxford University Press, Oxford 91-166
10. Panayiotopoulos C.P., and Chroni E. F-waves in clinical neurophysiology: a review. Methodological issues and overall value in peripheral neuropathies. Electroencephalogr Clin Neurophysiol 101 (1996) 365-374
11. Chaudhry V., Rowinsky E.K., Sartorius S.E., et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35 (1994) 304-311
12. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
13. Lentner C. Exact confidence limits for P. Geigy scientific tables (1982), Ciba-Geigy, Switzerland 89-102
14. Apfel S.C. Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. Cancer Invest 18 6 (2000) 564-573
15. Hilkens P.H., and ven den Bent M.J. Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 2 4 (1997) 350-361
16. Berger T., Malayeri R., Doppelbauer A., et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 33 9 (1997) 1393-1399
17. Gregg R.W., Molepo J.M., Monpetit V.J., et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurological tissue and morphological evidence of toxicity. J Clin Oncol 10 (1992) 795-803
18. Cavaletti G., Tredici G., Braga M., and Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133 (1995) 64-72
19. Sanfeliu C., Wright J.M., and Kim S.U. Neurotoxicity of isoniazid and its metabolites in cultures of mouse dorsal root ganglion neurons and hybrid neuronal cell line. Neurotoxicology 20 6 (1999) 935-944
20. Satya-Murti S., Howard L., Krohel G., and Wolf B. The spectrum of neurological disorder from vitamin E deficiency. Neurology 36 (1986) 917-921
21. Ko H.Y., and Park-Ko I. Electrophysiologic recovery after vitamin E-deficient neuropathy. Arch Phys Med Rehabil 80 8 (1999) 964-967
22. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 249 1 (2002) 9-17
23. Pace A., Savarese A., Picardo M., et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21 5 (2003) 927-931
24. McGuire W.P. How many more nails to seal the coffin of dose intensity?. Ann Oncol 8 4 (1997) 311-313
25. Thigpen J.T. Dose-intensity in ovarian carcinoma: hold, enough?. J Clin Oncol 15 4 (1997) 1291-1293
26. Tack D.K., Palmieri F.M., and Perez E.A. Anthracycline vs. nonanthracycline adjuvant therapy for breast cancer. Oncology (Huntingt) 18 11 (2004) 1367-1376
27. Diplock A.T. Safety of antioxidant vitamins and beta-carotene. Am J Clin Nutr 62 6 Suppl (1995) 1510S-1516S
28. Hathcock J.N., Azzi A., Blumberg J., et al. Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr 81 4 (2005) 736-745
29. Chaudhry V., Cornblath D.R., Corse A., et al. Thalidomide-induced neuropathy. Neurology 59 (2002) 1872-1875